Back

A pulse on
health
tech

Learn how consumer demand and cutting-edge solutions – from wearable technologies to AI-driven diagnostics – are reinvigorating health and biotech investment.

The golden age of health tech is here

Innovations, investments, and consumer demand are propelling the health tech industry into an era of growth and opportunity.

Read the Digital Story
layout-04 media

$3.9

trillion is the projected value of the U.S. biotech market by 20301

card icon

19%

CAGR is projected for the U.S. fitness tracker market between 2023 and 20302

card icon

1/2

of Americans say they prioritize their health, up from 42% in 20203

card icon

Sources: 1) Grand View Research (n.d.): Biotechnology Market Size, Share & Trend Analysis By Technology (Nanobiotechnology, DNA Sequencing, Cell-based Assays), By Application (Health, Bioinformatics), By Region, And Segment Forecasts, 2024 - 2030 2) Fortune Business Insights (5/13/2024): U.S. Fitness Tracker Market 3) McKinsey & Company (9/19/2022): Still feeling good: The US wellness market continues to boom.

The Big Picture

Investors are seeing potential opportunities thanks to cutting-edge biotech breakthroughs, more hospitals adopting med tech for patient care, and strong consumer demand for wellness solutions.

Discover more investor insights

Understand the trends behind the trends. From AI and other tech breakthroughs, to a wave of consumer demand for personal wellness solutions, learn how changes in this sector are driving potential investor opportunity.

Read More:

Personal health tech
layout-05 media
Check out the digital story · Check out the digital story · Check out the digital story · Check out the digital story ·

More Trend Stories

Trend Story

Smart cities, sustainable transportation

An example image

Trend Story

Trends across the generations

An example image

Trend Story

Frontiers in AI and automation

An example image

Risk Warning: Investment involves risk including the loss of capital. Disclaimer This document is being provided for informational purposes only. The information contained herein is confidential and is intended solely for the person to which it has been delivered. It may not be reproduced or transmitted, in whole or in part, by any means, to third parties without the prior consent of AXA Investment Managers US Inc. (the “Adviser”). This communication does not constitute on the part of AXA Investment Managers a solicitation or investment, legal or tax advice. Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

axaim-usa.com|© 2023 AXA Investment Managers. All rights reserved